The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins
- PMID: 31078566
- DOI: 10.1016/j.cca.2019.05.004
The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins
Abstract
A new concept to account for the process of postprandial remnant lipoprotein metabolism is proposed based on the characteristics of lipoprotein particles and their receptors. The characteristics of remnant lipoprotein (RLP) were investigated using an immuno-separation method. The majority of the postprandial lipoproteins increased after fat intake was shown to be VLDL remnants, not chylomicron (CM) remnants, based on the significantly high ratio of apoB100/apoB48 in the RLP and the high degree of similarity in the particle size of the apoB48 and apoB100 carrying lipoproteins, which fluctuate in parallel during a 6 h period after fat intake. The VLDL receptor was discovered as a receptor for TG-rich lipoprotein metabolism and is located in peripheral tissues such as skeletal muscle, adipose tissue, etc., but not in the liver. Postprandial VLDL particles are strongly bound and internalized into cells expressing the VLDL receptor. Ligands that bind to VLDL receptor, such as LPL and Lp(a), present in RLP. The presence of various specific ligands in VLDL remnants may enhance the capacity for binding to the VLDL receptor, which play the role primarily for energy delivery to the peripheral tissues, but is also a causal factor in atherogenic diseases when excessively and/or continuously remained in plasma.
Keywords: Adiponectin; ApoE; Chylomicron (CM) remnants; Fat load; Lipoprotein lipase (LPL); Low density lipoprotein (LDL) receptor; Lp(a); Metallothionein (I/II); PCSK9; Postprandial lipoproteins; Remnant lipoproteins (RLP); VLDL remnants; Very low density lipoprotein (VLDL) receptor.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Atherogenic postprandial remnant lipoproteins; VLDL remnants as a causal factor in atherosclerosis.Clin Chim Acta. 2018 Mar;478:200-215. doi: 10.1016/j.cca.2017.12.039. Epub 2018 Jan 4. Clin Chim Acta. 2018. PMID: 29307667 Review.
-
Postprandial remnant lipoproteins as targets for the prevention of atherosclerosis.Curr Opin Endocrinol Diabetes Obes. 2018 Apr;25(2):108-117. doi: 10.1097/MED.0000000000000393. Curr Opin Endocrinol Diabetes Obes. 2018. PMID: 29493553 Review.
-
Hypothesis II: The majority of VLDL-apoB48 remnants in postprandial plasma are derived from the liver, not from the intestine.Clin Chim Acta. 2019 Mar;490:12-16. doi: 10.1016/j.cca.2018.12.010. Epub 2018 Dec 14. Clin Chim Acta. 2019. PMID: 30553860
-
Hypothesis: Postprandial remnant lipoproteins are the causal factors that induce the insulin resistance associated with obesity.Clin Chim Acta. 2018 Oct;485:126-132. doi: 10.1016/j.cca.2018.06.029. Epub 2018 Jun 27. Clin Chim Acta. 2018. PMID: 29958888 Review.
-
Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity.Atherosclerosis. 2012 May;222(1):222-8. doi: 10.1016/j.atherosclerosis.2012.02.001. Epub 2012 Feb 7. Atherosclerosis. 2012. PMID: 22365426
Cited by
-
The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus.Cardiovasc Diabetol. 2022 Nov 24;21(1):257. doi: 10.1186/s12933-022-01652-z. Cardiovasc Diabetol. 2022. PMID: 36434633 Free PMC article.
-
Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights.Front Cardiovasc Med. 2022 Oct 4;9:993633. doi: 10.3389/fcvm.2022.993633. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36267630 Free PMC article. Review.
-
Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis.Front Pharmacol. 2022 Sep 2;13:974995. doi: 10.3389/fphar.2022.974995. eCollection 2022. Front Pharmacol. 2022. PMID: 36120312 Free PMC article.
-
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).Int J Mol Sci. 2022 Apr 13;23(8):4300. doi: 10.3390/ijms23084300. Int J Mol Sci. 2022. PMID: 35457118 Free PMC article. Review.
-
Metabolism of Triglyceride-Rich Lipoproteins.Handb Exp Pharmacol. 2022;270:133-156. doi: 10.1007/164_2021_520. Handb Exp Pharmacol. 2022. PMID: 34676434
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous